Search -

Displaying 21 - 40 of 716

Sort: Relevancy | Date

News Daily News

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Yael L. Maxwell

June 09, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Conference News EuroPCR 2025

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

Yael L. Maxwell

June 02, 2025

News Conference News EuroPCR 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

L.A. McKeown

May 30, 2025

News Conference News EuroPCR 2025

‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI

Michael O'Riordan

May 29, 2025

News Conference News EuroPCR 2025

Short DAPT in High-Bleeding-Risk Patients Reduces Recurrent Events: MASTER DAPT

Yael L. Maxwell

May 23, 2025

News Conference News European Congress on Obesity 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

News Daily News

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

Yael L. Maxwell

April 16, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Daily News

SCAD Story Fleshed Out by Clues About Causes, Treatment Risks

Yael L. Maxwell

March 13, 2025

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Daily News

Use of Secondary CVD Prevention Meds Still Meager Worldwide

Caitlin E. Cox

February 03, 2025

News Industry News

Genomadix Inc. Announces Health Canada License for Rapid Genetic Test to Aid Therapy Selection for Stroke and Cardiovascular Disease Patients

January 30, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

BMJ Investigation Revives Questions About PLATO, Ticagrelor

Todd Neale

December 20, 2024

News Daily News

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

Todd Neale

December 06, 2024

Presentation AHA 2024

Efficacy and safety of EdoxabaN in anticoagulant therapy after surgical Bioprosthetic vALVe replacement

Presenter: Chisato Izumi

November 17, 2024

Advertisement

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI

Short DAPT in High-Bleeding-Risk Patients Reduces Recurrent Events: MASTER DAPT

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

SCAD Story Fleshed Out by Clues About Causes, Treatment Risks

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Use of Secondary CVD Prevention Meds Still Meager Worldwide

Genomadix Inc. Announces Health Canada License for Rapid Genetic Test to Aid Therapy Selection for Stroke and Cardiovascular Disease Patients

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

BMJ Investigation Revives Questions About PLATO, Ticagrelor

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

Efficacy and safety of EdoxabaN in anticoagulant therapy after surgical Bioprosthetic vALVe replacement

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content